靶向经典WNT信号通路改善实验性硬皮病样慢性移植物抗宿主病
该研究探讨经典WNT通路在硬皮病样慢性GVHD(sclGVHD)中的作用。人sclGVHD皮损中WNT信号激活,β-连环蛋白核积聚增加且呈WNT偏向基因表达特征。使用G007-LK、吡维铵或盐霉素抑制WNT信号可预防实验性sclGVHD,且不影响移植物抗白血病效应。
要点
- 人sclGVHD皮损中经典WNT信号通路激活,β-连环蛋白核积聚增加。
- G007-LK、吡维铵或盐霉素可几乎完全预防两种小鼠模型的sclGVHD。
- 抑制WNT信号减少成纤维细胞释放细胞外基质和白细胞浸润,且不影响GVL。
核心结论
- 靶向经典WNT信号通路可改善实验性硬皮病样慢性GVHD,且不影响移植物抗白血病效应。
研究设计与样本
- 实验研究,使用B10.D2→BALB/c和LP/J→C57BL/6两种sclGVHD小鼠模型,并分析人sclGVHD皮损。
主要发现
- 人sclGVHD皮损中WNT信号激活,β-连环蛋白核积聚增加且呈WNT偏向基因表达特征。
- G007-LK、吡维铵或盐霉素几乎完全预防两种小鼠模型的sclGVHD临床和组织学特征。
- 抑制WNT信号减少成纤维细胞释放细胞外基质和白细胞浸润。
- 抑制WNT信号对移植物抗白血病效应无显著影响。
临床怎么用
- 吡维铵已在临床使用,端锚聚合酶抑制剂正在其他适应症临床试验中,提示WNT抑制策略具有转化潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic graft-versus-host disease (cGVHD) is a major life-threatening complication of allogeneic hematopoietic stem cell transplantation. The molecular mechanisms underlying cGVHD remain poorly understood, and targeted therapies for clinical use are not well established. Here, we examined the role of the canonical WNT pathway in sclerodermatous cGVHD (sclGVHD). WNT signaling was activated in human sclGVHD with increased nuclear accumulation of the transcription factor β-catenin and a WNT-biased gene expression signature in lesional skin. Treatment with the highly selective tankryase inhibitor G007-LK, the CK1α agonist pyrvinium, or the LRP6 inhibitor salinomycin abrogated the activation of WNT signaling and protected against experimental cGVHD, without a significant impact on graft-versus-leukemia effect (GVL). Treatment with G007-LK, pyrvinium, or salinomycin almost completely prevented the development of clinical and histological features in the B10.D2 (H-2d) → BALB/c (H-2d) and LP/J (H-2b) → C57BL/6 (H-2b) models of sclGVHD. Inhibition of canonical WNT signaling reduced the release of extracellular matrix from fibroblasts and reduced leukocyte influx, suggesting that WNT signaling stimulates fibrotic tissue remodeling by direct effects on fibroblasts and by indirect inflammation-dependent effects in sclGVHD. Our findings may have direct translational potential, because pyrvinium is in clinical use, and tankyrase inhibitors are in clinical trials for other indications.
引用
- Zhang Y, Shen L, Dreißigacker K, et al. Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease. Blood. 2021. PMID: 33529322. doi:10.1182/blood.2020008720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。